newsfilter
← Latest News
ACCESS Newswire·

Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts

  • Ascendiant Capital Markets issued an updated equity research report on IGC Pharma (NYSE: IGC) on April 8, 2026.
  • The analyst raised the price target for IGC shares to $5.25 per share.
  • The report cites expected positive clinical data & progress in 2026 as strong catalysts for the stock.
  • IGC Pharma is a clinical-stage biotechnology company using AI to develop treatments for Alzheimer's & metabolic disorders.
  • The company's lead asset, IGC-AD1, is currently in a Phase 2 CALMA clinical trial for agitation in Alzheimer's dementia.
  • IGC's pipeline includes TGR-63 for amyloid plaques & early-stage programs targeting tau proteins & neurodegeneration.
  • The press release includes standard forward-looking statements & disclaimers regarding risks related to regulatory approval, AI algorithms, & economic conditions.